

### Ibrutinib 140mg, 280mg, 420mg and 560mg film-coated tablets (Imbruvica®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2485	In combination with rituximab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.	Not routinely available as not recommended for use in NHS Scotland	20/04/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/ibrutinib-imbruvica-non-sub-smc2485/>

#### Other Decision Specified

**Date of ADTC** 20/04/2022

---

### Carfilzomib 10mg, 30mg and 60mg powder for solution for infusion (Kyprolis®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2484	In combination with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHS Scotland	20/04/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/carfilzomib-kyprolis-non-sub-smc2484/>

#### Other Decision Specified

**Date of ADTC** 20/04/2022

---

### Fedratinib 100mg hard capsules (Inrebic®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2462	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/07/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/fedratinib-inrebic-abb-smc2462/>

### Other Decision Specified

**Date of ADTC** 20/04/2022

---

## Upadacitinib 15mg and 30mg prolonged-release tablets (Rinvoq®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2417	<p>For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.</p> <p>SMC restriction: patients who have had an inadequate response to at least one conventional systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.</p>	<p>Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by</p>	31/07/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/upadacitinib-rinvoq-full-smc2417/>

### Other Decision Specified

**Date of ADTC** 20/04/2022

---

## Risankizumab 150mg solution for injection in a prefilled syringe or pen (Skyrizi®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2459	<p>Alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs(DMARDs). SMC restriction: (i) patients whose disease has not responded adequately or who have been intolerant to two previous conventional disease-modifying antirheumatic drug (DMARD) therapies but have not received biologic DMARD therapy (biologic-naïve population); (ii) patients whose disease has not responded adequately to conventional DMARDs and one or more tumour necrosis factor (TNF) inhibitors (biologic-experienced population); and (iii) patients in whom TNF inhibitors are contraindicated or not tolerated.</p>	Not routinely available as there is a local preference for alternative medicines	20/04/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/risankizumab-skyrizi-abb-smc2459/>

### Other Decision Specified

**Date of ADTC** 20/04/2022

### Atidarsagene autotemcel 2 to 10 x 10<sup>6</sup> cells/ml dispersion for infusion (Libmeldy®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2413	<p>Treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity:</p> <ul style="list-style-type: none"><li>- in children with late infantile or early juvenile forms, without clinical manifestations of the disease,</li><li>- in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.</li></ul>	Available in line with national guidance	20/04/2022

#### Web Links

<https://www.scottishmedicines.org.uk/medicines-advice/atidarsagene-autotemcel-libmeldy-ultra-orphan-smc2413/>

#### Other Decision Specified

Date of ADTC 20/04/2022

---

## Venetoclax 10mg, 50mg and 100mg film-coated tablets (Venclyxto®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2412	In combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/07/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/venetoclax-venclyxto-full-smc2412/>

### Other Decision Specified

**Date of ADTC** 20/04/2022

## Belimumab powder for concentrate and solution for injection in pre-filled pen (Benlysta®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2483	In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.	Not routinely available as not recommended for use in NHS Scotland	20/04/2022

**Web Links** <https://www.scottishmedicines.org.uk/medicines-advice/belimumab-benlysta-non-sub-smc2483/>

### Other Decision Specified

**Date of ADTC** 20/04/2022